Kalvista Pharmaceuticals

KalVista Pharmaceuticals Launched With 8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema

Older News

SOUTHAMPTON, England, August 23, 2011 - KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised 8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy